• Facebook
  • Twitter
  • Youtube
  • Instagram
  • LinkedIn
  • Rss
  • Store
  • Donate
NCCS - National Coalition for Cancer Survivorship
  • About
        • About Us

        • NCCS is the oldest cancer survivor-led non-profit organization in America. We advocate for quality cancer care for all touched by cancer.

        • About NCCS

        • Our Mission
        • What is Advocacy?Learn about the different types of cancer advocacy, from personal advocacy to public interest advocacy.
        • Our HistoryRead how NCCS’s leaders coined the term “cancer survivor,” and established the nation’s first survivor-led non-profit organization.
        • Our Team
        • Financial Information
        • Employment
        • Contact Us
        • Support Our Mission

        • Make A GiftSupport our mission of quality cancer care for all with a gift to NCCS.
        • The 1986 ClubMake a monthly commitment to support NCCS, empower cancer survivors, and advance public policy.
        • Ways to GiveLearn about other ways you can contribute to NCCS such as planned giving, employer matches, shopping online, and more.
        • Partnerships
  • News
    • NCCS News
    • Advocate SpotlightEach month, NCCS highlights a cancer survivorship advocate, sharing their story and the work they do in their communities.
    • Policy CommentsRead NCCS’s comments to Congress, HHS, and other federal policymakers in Washington, DC on proposed rules and legislation.
    • Issue StatementsRead NCCS statements on pressing issues and developments in Washington affecting cancer survivors and their families.
  • Policy
        • Policy

        • Public policy is government action, in the form of legislation, regulation, funding, and other actions. Public policy affects people with cancer and the cancer care system in many ways.

        • Our Policy Priorities

        • Quality Cancer CareQuality cancer care is essential for patients. Learn how NCCS and others define quality.
        • Access to CareNCCS believes cancer care and clinical trials should be affordable and accessible to everyone.
        • Health EquityThe cancer experience is not the same for everyone. NCCS works on policy efforts to reduce disparities in outcomes.
        • Current Issues

        • Comprehensive Cancer Survivorship Act (CCSA)The CCSA is a large comprehensive bill introduced in Congress that aims to improve quality of care in all stages of a diagnosis.
        • Cancer Care Planning and Communications Act (CCPCA)CCPCA is a bill that would provide a billable Medicare service code for cancer care planning.
        • DIEP Flap AccessNCCS advocates for protection of access to DIEP Flap Breast Reconstruction Surgery for all breast cancer survivors.
        • Policy CommentsRead NCCS’s comments to Congress, HHS, and other federal policymakers in Washington, DC on proposed rules and legislation.
        • Issue StatementsRead NCCS statements on pressing issues and developments in Washington affecting cancer survivors and their families.
        • Quality Measurement Research
  • Get Involved
        • Get Involved

        • Whether you’re new to cancer advocacy or already have experience as an advocate, there are numerous ways you can get involved with NCCS.

        • Join NCCS

        • Cancer Policy and Advocacy Team (CPAT)CPAT is a program for survivors and caregivers to learn about pressing issues that affect quality cancer care, in order to be engaged as advocates in public policy.
        • Elevating SurvivorshipA patient-led initiative — NCCS mentors advocates (Elevate Ambassadors) to fill vital gaps in survivorship care in their community.
        • Survivorship ChampionsAn NCCS program for clinicians and researchers who are interested in improving care for cancer survivors.
        • Advocacy OpportunitiesThis page provides a list of upcoming events, webinars, conferences, and advocacy campaigns from NCCS and other leading cancer organizations.
        • Connect with Us

        • Subscribe to NCCS Updates
        • Follow NCCS on Social Media
        • Survivor Stories
        • Cancerversary
        • Support NCCS

        • Make A Gift
        • Ways to Give
        • The 1986 Club
  • Survivorship Survey
        • State of Cancer Survivorship

        • NCCS conducts an annual State of Survivorship Survey, in partnership with Edge Research, to delve into the cancer patient and survivor journey. This study captures a range of perspectives to better understand how NCCS can support its mission to advocate for quality cancer care for all.

        • Reports by Year

        • 2023 Survey ReportThe 2023 Survey explored the caregiver experience for the first time, and features new data on the effect of cancer treatment on employment.
        • 2022 Survey ReportThe 2022 Survey found significant disparities in cancer care that impact people of color, young adults, women, and those with metastatic cancer, at higher rates.
        • 2021 Survey ReportThe 2021 Survey demonstrated that when patients receive quality care, have excellent support, and have financial resources, they are more likely to have positive outcomes.
        • 2020 Survey ReportIn the 2020 Survey, survivors reported that their care team is not helpful at addressing some common side effects of their cancer such as fatigue, anxiety, and depression.
  • Survivorship Checklist
        • Cancer Survivorship Checklist

        • The Cancer Survivorship Checklist is designed to be a simple, straightforward tool patients and caregivers can use as a guide for information critical to their care wherever they are on the cancer care continuum.

        • Start Your Cancer Survivorship Checklist
        • Survivorship Checklist Guide for Clinicians
        • Resources for Cancer Survivors

        • Survivorship ResourcesA collection of resources that provide information about navigating the cancer journey.
        • Cancer RehabilitationA supportive health care service that helps improve a person’s functioning during and after cancer treatment.
        • Integrative OncologyA field that combines traditional cancer treatments with therapies that support a person’s natural healing ability.
  • Resources
        • Resources

        • NCCS provides a wide variety of resources for both patients and caregivers.

        • Resources for Survivors and Caregivers

        • Cancer Survival ToolboxA free, award-winning audio program created by leading cancer organizations to help people better meet & understand the challenges of their illness.
        • Telehealth
        • Care Planning for Cancer Survivors
        • Remaining Hopeful
        • Self Advocacy
        • Talking With Your Doctor
        • Taking Charge of Your Care
        • Order Our Resources
        • Resources for Health Care Professionals

        • Tools For Care Providers
        • Telehealth Project
        • Survivorship Champions Webinars
        • Survivorship Checklist Guide for Clinicians
  • Events
    • Ellen L. Stovall Award
      • 2023 Winners
      • Awardees
      • Reception and Sponsorship
      • Committees
      • Nominations
    • Cancer Policy Roundtable (CPR)
      • Spring 2023 CPR
      • Fall 2022 CPR
      • Spring 2022 CPR
    • 2023 Survivorship Survey
    • Webinars
  • 0

Your generous year-end donation will be matched $1 for $1    DONATE

Centers for Medicare Medicaid Services

NCCS and Cancer Groups Make Recommendations to CMS Regarding Proposed 2021 Hospital Outpatient Prospective Payment System (OPPS)

October 6, 2020/in CMS, NCCS News, Policy Comments Access to Care, Drug Pricing, Health Care Coverage, Payment Reform, Quality Cancer Care NCCS News, Policy Comments

NCCS joined with other cancer patient and provider groups in a comment letter to the Centers for Medicare and Medicaid Services (CMS) regarding the proposed rule related to the hospital outpatient prospective payment system. Among the issues outlined in the letter is a concern about an additional reduction in payment for drugs in the 340B program, a program that helps hospitals who serve vulnerable and low-income patients access prescription drugs. The letter advises against another reduction and recommends that CMS work with the Health Resources and Services Administration to conduct an evaluation of the 340B.

Additionally, the comment letter commends CMS for addressing the date of service rule for cancer-related, protein-based laboratory testing and encourages the agency to consider the same exceptions to these tests for other diseases in future rulemaking efforts.

We commend CMS for its proposal to exclude certain cancer-related, protein-based Multianalyte Assays with Algorithmic Analyses (MAAAs) from the OPPS packaging policy. By excepting these cancer tests from the date-of-service policy and allowing them to be billed directly to Medicare by laboratories, delays in testing can be addressed and patient diagnosis treatment decision-making, and initiation of care can proceed without interruption or unreasonable delay.

Read the entire comment letter below.

Download the Comment Letter [PDF] »


CANCER LEADERSHIP COUNCIL

A PATIENT-CENTERED FORUM OF NATIONAL ADVOCACY ORGANIZATIONS
ADDRESSING PUBLIC POLICY ISSUES IN CANCER

October 5, 2020

The Honorable Seema Verma
Administrator
Centers for Medicare & Medicaid Services
Department of Health and Human Services
Hubert H. Humphrey Building
200 Independence Avenue SW
Washington, DC 20201

RE: CMS-1736-P, Medicare Program: Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; New Categories for Hospital Outpatient Department Prior Authorization Process; Clinical Laboratory Fee Schedule; Laboratory Date of Service Policy; Overall Hospital Quality Star Rating Methodology; and Physician-Owned Hospitals

Dear Administrator Verma:

The undersigned organizations represent cancer patients, health care professionals, and researchers. We are pleased to have the opportunity to comment on the proposed rule related to the hospital outpatient prospective payment system, laboratory date of service policy, and other matters.

We note that our comments and advice are offered in the midst of a pandemic that has caused serious disruptions in the delivery of cancer care and has adversely affect access to cancer screening and routine care that might lead to cancer diagnosis. The effects on patients are serious, as they may suffer worsening of disease while treatment is delayed, or their cancer may be diagnosed at a later date and at a later stage. Both providers and patients have worked hard to address the challenges to delivering and receiving cancer care in the time of a pandemic, embracing telehealth services and ensuring proper use of personal protective equipment and other mitigation strategies to permit safe delivery of cancer care face-to-face. All the actions taken to address the pandemic bear costs, both in health terms and financially. We note this extraordinary time to suggest that reductions in reimbursement be approached with care. Additional challenges to the health care system may only serve to adversely affect patient access to quality care.

CY 2021 OPPS Payment Methodology for 340B Purchased Drugs

The Centers for Medicare & Medicaid Services (CMS) proposes to revise payment policy for outpatient drugs that are purchased under the 340B program. For calendar year (CY) 2018, CMS made a substantial change in payment for drugs purchased through the 340B Program. In place of the payment rate of ASP plus 6%, the agency set the Medicare payment rate at ASP minus22.5%. For calendar year 2019, this payment standard was extended to 340B drugs furnished by non-excepted off-campus provider-based departments.

The United States Court of Appeals for the District of Columbia, in a ruling on July 31, 2020, affirmed that CMS has the authority to reduce Medicare payment rates for 340B drugs reimbursed through the outpatient prospective payment system (OPPS).

CMS proposes for calendar year 2021 to further reduce Medicare payment for 340B drugs. For 2021 and years beyond, the agency proposes to adopt a rate of ASP minus 34.7 percent, with a 6 percent add-on amount for overhead and handling costs, for a proposed net rate of ASP minus 28.7 percent. The agency indicates that the proposed payment rate is based on data on drug acquisition costs in calendar year 2018 and 2019 that was collected through the Hospital Acquisition Cost Survey for 340B-Acquired Specified Covered Drugs.

We have serious reservations about relying on a survey that was undertaken in the middle of the pandemic as the basis for substantial reductions in payment for 340B drugs. According to CMS, only 7% of respondents answered the detail survey, 55% responded to the quick survey option, and 38% did not respond. We are not surprised that the response to this survey was not stronger, because hospitals were asked to respond at a time when their resources were dedicated to coronavirus pandemic response.

Our fundamental concern is that the reduced reimbursement rate that is based on a less-than-robust survey will adversely impact the vulnerable and low-income patients that the 340B program is intended to help and the institutions that serve those patients. The 340B program is of importance to institutions that serve a significant volume of cancer patients who depend significantly on drug therapies as part of their comprehensive cancer treatment.

We understand that there is interest in ensuring that the 340B program meets its original intent. Rather than apply additional reimbursement reductions to the program, we recommend that CMS, working with the Health Resources and Services Administration, undertake an evaluation of the 340B program to consider its alignment with the original goals and aims of the program. We also recommend that the evaluation focus on the appropriate size of the program and the kind of program safeguards that should be implemented. Reforms of the program should be considered after an evaluation of the program that engages all stakeholders. Another payment reduction will not serve the purpose of guaranteeing that the program operates to serve vulnerable patients in receipt of quality and affordable health care.

Laboratory Date of Service Rule

All of our organizations share the goal of ensuring that cancer patients receive care that is best for them and meets their needs and wishes. No matter the decision that cancer patients make about their care, appropriate and accurate diagnosis is critical to their decision-making. This includes access in timely and affordable fashion to clinical diagnostic laboratory tests.

We commend CMS for its proposal to exclude certain cancer-related, protein-based Multianalyte Assays with Algorithmic Analyses (MAAAs) from the OPPS packaging policy. By excepting these cancer tests from the date-of-service policy and allowing them to be billed directly to Medicare by laboratories, delays in testing can be addressed and patient diagnosis, treatment decision-making, and initiation of care can proceed without interruption or unreasonable delay.

Although cancer care providers and their patients have worked hard to address pandemic-related disruptions in care, we are concerned that delays and disruptions early in the pandemic and the impact of those delays on outcomes. There have been other disruptions related to cancer, including delays in screening that may result in diagnosis at a later stage of disease.

We are pleased that, at a time when the cancer community is working hard to address pandemic-related care disruptions, the agency has addressed the date of service rule at least for cancer-related, protein-based MAAAs. We encourage CMS to consider the same exceptions to MAAAs for other diseases in future rulemaking efforts.

**********

We appreciate the opportunity to comment on these issues that affect cancer patients’ access to quality care.

Sincerely,

Cancer Leadership Council
CancerCare
Fight Colorectal Cancer
Hematology/Oncology Pharmacy Association
LUNGevity Foundation
Lymphoma Research Foundation
National Coalition for Cancer Survivorship
Prevent Cancer Foundation
Susan G. Komen


Tags: CMS, drug pricing, Medicare, policy comments
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
https://canceradvocacy.org/wp-content/uploads/Centers-for-Medicare-Medicaid-Services.jpg 515 1030 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2020-10-06 13:13:462020-10-23 14:46:00NCCS and Cancer Groups Make Recommendations to CMS Regarding Proposed 2021 Hospital Outpatient Prospective Payment System (OPPS)

Latest News

Webinar – Reconnecting to Life After Cancer: Permission to Feel

December 7, 2023
The National Coalition for Cancer Survivorship (NCCS) presents "Reconnecting to Life After Cancer: Permission to Feel," a webinar featuring…
Read more
https://canceradvocacy.org/wp-content/uploads/Kathy-Washburn-CPAT-Webinar-Cancer-Coach-post.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2023-12-07 18:00:382023-12-07 18:00:38Webinar – Reconnecting to Life After Cancer: Permission to Feel
NCCS Advocate Spotlight: Tamron Little

The Advocate Within: Tamron Little’s Remarkable Journey of Turning Trauma into Triumph

December 6, 2023
Advocate Spotlight: Tamron Little Tamron Little was a 21-year-old college student and pregnant with her first child when she was…
Read more
https://canceradvocacy.org/wp-content/uploads/Tamron-Little-Advocate-Spotlight-Blog-Banner.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2023-12-06 10:24:262023-12-06 10:24:26The Advocate Within: Tamron Little’s Remarkable Journey of Turning Trauma into Triumph
Advocate Spotlight: Mary Glen, with photo of Mary.

The Not-So-Good Cancer: Mary Glen’s Inspiring Advocacy Journey

November 8, 2023
Advocate Spotlight: Mary Glen Mary Glen was serving as an active-duty Army officer, deployed to South Korea in August 2020. Just…
Read more
https://canceradvocacy.org/wp-content/uploads/Mary-Glen-Advocate-Spotlight-Blog-Banner.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2023-11-08 11:55:412023-11-08 11:55:41The Not-So-Good Cancer: Mary Glen’s Inspiring Advocacy Journey

Take Action

Link to: Survivorship Champions

Become a Survivorship Champion

Survivorship Champions is a program for all clinicians and researchers, both oncology and primary care, who are interested in improving survivorship care and primary care’s role in caring for cancer survivors.

Learn More and Join »
Link to: Cancer Policy and Advocacy Team (CPAT)

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Learn More and Join »
Link to: Survivor Stories

Share Your Story

NCCS represents the millions of Americans who share a common experience – living with, through and beyond a cancer diagnosis. By sharing your story of how you have been touched by cancer, you are supporting the national cancer survivorship movement.

Share Your Story »

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

  • This field is for validation purposes and should be left unchanged.

  • About
    • Our Mission
    • What is Advocacy?
    • Our History
    • Our Team
    • Financial Information
    • Employment
    • Contact Us
    • Make A Gift
    • The 1986 Club
    • Ways to Give
    • Partnerships
  • News
    • NCCS News
    • Advocate Spotlight
    • Policy Comments
    • Issue Statements
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Comprehensive Cancer Survivorship Act (CCSA)
    • Cancer Care Planning and Communications Act (CCPCA)
    • DIEP Flap Access
    • Policy Comments
    • Issue Statements
    • Quality Measurement Research
  • Get Involved
    • Cancer Policy and Advocacy Team (CPAT)
    • Survivorship Champions
    • Elevating Survivorship
    • Advocacy Opportunities
    • Subscribe to NCCS Updates
    • Follow NCCS on Social Media
    • Survivor Stories
    • Cancerversary
    • Make A Gift
    • The 1986 Club
    • Ways to Give
  • Survivorship Survey
    • 2023 Survey Report
    • 2022 Survey Report
    • 2021 Survey Report
    • 2020 Survey Report
  • Survivorship Checklist
    • Start Your Cancer Survivorship Checklist
    • Survivorship Resources
    • Cancer Rehabilitation
    • Integrative Oncology
    • Survivorship Checklist Guide for Clinicians
  • Resources
    • Cancer Survival Toolbox
    • Telehealth
    • Care Planning for Cancer Survivors
    • Remaining Hopeful
    • Self Advocacy
    • Talking With Your Doctor
    • Taking Charge of Your Care
    • Order Our Resources
    • Tools For Care Providers
    • Telehealth Project
    • Survivorship Champions Webinars
    • Survivorship Checklist Guide for Clinicians
  • Events
    • Ellen L. Stovall Award
      • 2023 Winners
      • Awardees
      • Reception and Sponsorship
      • Committees
      • Nominations
    • Cancer Policy Roundtable (CPR)
      • Spring 2023 CPR
      • Fall 2022 CPR
      • Spring 2022 CPR
    • 2023 Survivorship Survey
    • Webinars
  • Search
  • Cart

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930  |  Silver Spring, MD 20910
877-NCCS-YES  |  info@canceradvocacy.org
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2023 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.

NCCS and Cancer Groups Urge National Academy of Medicine to Include Cancer Patients...NCCS CancerAdvocacy.orgCenters for Medicare and MedicaidNCCS Recommends Making COVID-19 Medicare Telehealth Coverage Expansion Perm...
Scroll to top
Download the Survey Report

"*" indicates required fields

Fill out the form below, and we’ll send the survey report, detailed presentation, and infographic to your email.
Name*
I am a...*
Select any/all that apply.
Consent*
By downloading the survey materials, you will receive updates and information from NCCS via email, which you may unsubscribe from at any time. Your information will never be sold to any third parties.
This field is for validation purposes and should be left unchanged.

Download the Survey Report

"*" indicates required fields

Fill out the form below, and we’ll send the survey report, detailed presentation, and infographic to your email.
Name*
I am a...*
Select any/all that apply.
Consent*
By downloading the survey materials, you will receive updates and information from NCCS via email, which you may unsubscribe from at any time. Your information will never be sold to any third parties.
This field is for validation purposes and should be left unchanged.

Get Updates From NCCS

Be the first to hear about cancer policy and survivorship issues! Subscribe and receive the biweekly NCCS Health Care Roundup, invites to webinars and events, and more.

  • This field is for validation purposes and should be left unchanged.

Connect With Us

Twitter     Facebook     Instagram     LinkedIn     YouTube

Harmar Brereton, MD

Founder
Northeast Regional Cancer Institute

 

“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”

—Karen M. Saunders
President, Northeast Regional Cancer Institute